(E)-2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate | 469866-31-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate
• 英文别名: IFB-088 acetate；acetic acid;2-[(E)-(2-chlorophenyl)methylideneamino]guanidine
• CAS: 469866-31-7
• 化学式: C₂H₄O₂*C₈H₉ClN₄
• 分子量: 256.692
• InChiKey: WEXITTWZMLUGNU-NKPNRJPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.25
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT.<br/>[FR] PROCÉDÉ DE TRAITEMENT DE CANCER AVEC UNE COMBINAISON DE DÉRIVÉS DE BENZYLIDÈNEGUANIDINE ET D'AGENT CHIMIOTHÉRAPEUTIQUE
  申请人：INFLECTIS BIOSCIENCE

  公开号：WO2017021216A1

  公开（公告）日：2017-02-09

  The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

  本发明涉及一种用于治疗胶质瘤或改善胶质瘤效果，特别是胶质母细胞瘤的组合物，所述组合物包括选自以下化合物组的第一活性剂，即化合物(I)或其药学上可接受的盐(I)，以及第二活性剂，即替莫唑胺或其药学上可接受的盐；以及一种药学上可接受的载体。
• [EN] NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES<br/>[FR] NOUVELLES UTILISATIONS THÉRAPEUTIQUES DE DÉRIVÉS DE LA BENZYLIDÈNE-GUANIDINE DANS LE TRAITEMENT DE PROTÉOPATHIES
  申请人：INFLECTIS BIOSCIENCE

  公开号：WO2016001389A1

  公开（公告）日：2016-01-07

  The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.

  本发明涉及一种化合物（I）的新用途，或其互变异构体和/或药用盐，在治疗与PPP1R15A途径相关的紊乱，与蛋白质错误折叠应激相关，特别是与在tau病、α-突触核蛋白病、多聚谷氨酸和多聚丙氨酸疾病、白质病、囊性纤维化、多发性硬化、溶酶体贮积疾病、淀粉样变性疾病、炎症、代谢紊乱、心血管疾病、骨质疏松症、神经系统创伤、缺血等相关的错误折叠蛋白的积累。
• Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
  申请人：InFlectis BioScience

  公开号：US10675257B2

  公开（公告）日：2020-06-09

  The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

  本发明涉及一种用于治疗胶质瘤或改善胶质瘤（尤其是胶质母细胞瘤）影响的组合物，其中所述组合物包含选自由式（I）化合物或其药学上可接受的盐、（I）和第二活性剂（即替莫唑胺或其药学上可接受的盐）组成的组中的第一活性剂；以及药学上可接受的载体。
• Therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
  申请人：InFlectis BioScience

  公开号：US10709677B2

  公开（公告）日：2020-07-14

  The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.

  本发明涉及式（I）化合物或其同系物和/或其药学上可接受的盐在治疗与 PPP1R15A 通路相关且与蛋白质错误折叠应激相关的疾病中的新用途，特别是与选自牛磺酸病、多谷氨酰胺和多丙氨酸疾病、白质营养不良、囊性纤维化、多发性硬化症、溶酶体贮存疾病、淀粉样变性疾病中的错误折叠蛋白质累积相关的疾病中的新用途、突触核蛋白病、多谷氨酰胺和多丙氨酸疾病、白质营养不良、囊性纤维化、多发性硬化、溶酶体贮存紊乱、淀粉样变性疾病、炎症、代谢紊乱、心血管疾病、骨质疏松症、神经系统创伤、缺血。
• NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES
  申请人：InFlectis BioScience

  公开号：EP3164123A1

  公开（公告）日：2017-05-10